Menu
25/06/2007
Court challenge over Alzheimer's drugs
A decision by the government's medicines watchdog to refuse to fund Alzheimer's drugs for patients in the early stages of the disease is being challenged in the High Court.
The action has been brought by two drugs companies - Easai and Pfizer - as well as the Alzheimer's Society.
The case centres on three drugs - donepezil, rivastigmine and galantamine. The National Institute for Health and Clinical Excellence (Nice) published guidance last November, which recommended that the drugs should only be prescribed to people in the moderate stages of the disease, because, at a cost of £2.50 per day, they were not cost effective.
Easai, Pfizer and the Alzheimer's Society are arguing that Nice's appraisal process was flawed and unfair.
Neil Hunt, Chief Executive of the Alzheimer's Society, told the BBC: "These treatments have benefited so many families already - where is the justice in Nice's decision to snatch them away?
"We have to fight Nice's fatally flawed process, which has failed to recognise the benefits these treatments have for carers."
However, Andrew Dillon, chief executive of Nice, told the BBC that their processes were "transparent and fair". He said: "The reality is that, for Alzheimer's disease, drugs are only part of the care that needs to be offered.
"Non-drug interventions have an important part to play and the evidence indicates that drugs are simply not effective for some patients."
The case, which is being heard before Mrs Justice Dobbs at the High Court in London, is expected to last four days.
(KMcA)
The action has been brought by two drugs companies - Easai and Pfizer - as well as the Alzheimer's Society.
The case centres on three drugs - donepezil, rivastigmine and galantamine. The National Institute for Health and Clinical Excellence (Nice) published guidance last November, which recommended that the drugs should only be prescribed to people in the moderate stages of the disease, because, at a cost of £2.50 per day, they were not cost effective.
Easai, Pfizer and the Alzheimer's Society are arguing that Nice's appraisal process was flawed and unfair.
Neil Hunt, Chief Executive of the Alzheimer's Society, told the BBC: "These treatments have benefited so many families already - where is the justice in Nice's decision to snatch them away?
"We have to fight Nice's fatally flawed process, which has failed to recognise the benefits these treatments have for carers."
However, Andrew Dillon, chief executive of Nice, told the BBC that their processes were "transparent and fair". He said: "The reality is that, for Alzheimer's disease, drugs are only part of the care that needs to be offered.
"Non-drug interventions have an important part to play and the evidence indicates that drugs are simply not effective for some patients."
The case, which is being heard before Mrs Justice Dobbs at the High Court in London, is expected to last four days.
(KMcA)
Related UK National News Stories
Click here for the latest headlines.
01 March 2005
Alzheimer's drugs could be withdrawn
The National Institute of Clinical Excellence (NICE) has recommended the withdrawal of three drugs frequently used to help treat the symptoms of Alzheimer's disease.
Alzheimer's drugs could be withdrawn
The National Institute of Clinical Excellence (NICE) has recommended the withdrawal of three drugs frequently used to help treat the symptoms of Alzheimer's disease.
10 August 2007
Court Orders Review Of Alzheimer's Guidelines
A high court judge has ordered a review of guidelines on the way it decides which Alzheimer's patients are given three drugs to treat the brain-destroying disease.
Court Orders Review Of Alzheimer's Guidelines
A high court judge has ordered a review of guidelines on the way it decides which Alzheimer's patients are given three drugs to treat the brain-destroying disease.
23 January 2006
Anger over Alzheimer's drugs ruling
The revised guidance on drugs for the treatment of Alzheimer's disease has been greeted with anger by Alzheimer's charities.
Anger over Alzheimer's drugs ruling
The revised guidance on drugs for the treatment of Alzheimer's disease has been greeted with anger by Alzheimer's charities.
07 September 2009
Brixton Drug Gang Get Long Sentences
A gang of criminals who ran a lucrative drug dealing network from a car tyre shop in Brixton were sentenced last week to a total of 81 years in prison. Nine men, who were previously convicted of conspiracy to supply class A drugs, appeared at Kingston Crown Court today to hear their sentences.
Brixton Drug Gang Get Long Sentences
A gang of criminals who ran a lucrative drug dealing network from a car tyre shop in Brixton were sentenced last week to a total of 81 years in prison. Nine men, who were previously convicted of conspiracy to supply class A drugs, appeared at Kingston Crown Court today to hear their sentences.
15 April 2008
Court Battle Over Alzheimer's Drug
Almost 100,000 patients a year suffering from Alzheimer's will be refused drugs used by the NHS to fight the disease, the Court of Appeal has been told. Drugs company EISAI, manufacturer of Aricept, is contesting a decision to restrict access to patients in the later stages of the disease.
Court Battle Over Alzheimer's Drug
Almost 100,000 patients a year suffering from Alzheimer's will be refused drugs used by the NHS to fight the disease, the Court of Appeal has been told. Drugs company EISAI, manufacturer of Aricept, is contesting a decision to restrict access to patients in the later stages of the disease.
-
Northern Ireland WeatherToday:After a dry start this morning rain will spread from the northwest across all parts. This afternoon will be dull with some patchy rain and drizzle. Becoming much milder through the afternoon. Maximum temperature 11 °C.Tonight:A cloudy evening and night with a little light rain or drizzle, perhaps some clear periods developing along the east coast. A very mild night everywhere. Minimum temperature 10 °C.
